Series date: 
10/01/2019 - 4:30pm EDT to 12/31/2023 - 5:30pm EST

COURSE DESCRIPTION:
A multidisciplinary team approach to care is fostered through peer-to-peer discussion and collaboration. The team discussion pertaining to diagnosis and treatment includes radiological and pathological findings and immunohistochemical testing to bridge gaps across the continuum of care and enhance the overall quality of patient-centered oncology care.

 

TARGET AUDIENCE:
Medical Oncologists, Radiation Oncologists, General Surgeons, Pathologists, Radiologists, Pharmacists, Nurses, Social Workers, Radiologic Technologists, Patient Care Facilitators and all Personnel involved in the care of the hematology cancer patient.
 
EDUCATIONAL OBJECTIVES:

•    Improve clinical decision making, clinical outcomes, and patient experience via a multidisciplinary team approach. Group discussion include prospective patient care management, national treatment guidelines, staging, and options and eligibility for genetic testing, clinical research studies, and supportive care services.


•    Develop a comprehensive treatment plan for hematology oncology patients leveraging imaging and pathology testing results and meet Commission on Cancer accreditation standards compliance. 
 

FACULTY:

 

Ariel Perez, M.D., director and moderator of this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentations or discussions will not include off-label or unapproved product usage.

Yuliya Linahres, M.D., director and moderator of this educational activity, is a consultant for Seagen, ADC, Abbvie, Novartis, Celgene, BeiGene, Kyowa, Alexion, Genentech, AstraZeneca, GSK, Incyte, Janssen and  Pfizer and has indicated that the presentations or discussions will not include off-label or unapproved product usage.

All of the relevant financial relationships listed for this individual have been mitigated.

Rebecca S. Raffou and Marjorie Salomon, faculty of this educational activity, have no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentations or discussions will not include off-label or unapproved product usage.

Cristhian Alegria, Casey Reed and others involved in the planning, development, and editing/review of the content have relevant financial relationships to disclose with ineligible companies*:

*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
 

Disclosure Policy and Disclaimer

ACCREDITATION:
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.    

Baptist Health South Florida designates these live activities for a maximum of 1 AMA PRA Category 1 Credit™. each. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

These activities have been approved for 1 credit hour, CE Broker Course #20-633182 by the Florida Boards of Medicine and Osteopathic Medicine.

image

American Board of Surgery - Maintenance of Certification (MOC) - Accredited CME - Complex General Surgical Oncology

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Successful completion of this course is submitted to specialty boards through the ACCME's PARS system. 

Series location: 
Miami Cancer Institute
MCI Conference Room 3N110
5th Floor Training Room
Miami, FL 33176
United States

Sessions

Sessionsort descending Date
Hematology Tumor Board 07/12/2021 - 7:30am to 8:30am EDT
Hematology Tumor Board 08/09/2021 - 7:30am to 8:30am EDT
Hematology Tumor Board 10/11/2021 - 7:30am to 8:30am EDT
Hematology Tumor Board 11/08/2021 - 7:30am to 8:30am EST
Hematology Tumor Board 12/13/2021 - 9:00am to 10:00am EST
Hematology Tumor Board 01/10/2022 - 9:00am to 10:00am EST
Hematology Tumor Board 02/14/2022 - 9:00am to 10:00am EST
Hematology Tumor Board 03/14/2022 - 9:00am to 10:00am EDT
Hematology Tumor Board 04/11/2022 - 9:00am to 10:00am EDT
Hematology Tumor Board 05/09/2022 - 9:00am to 10:00am EDT

Pages